Is Pfizer Inc. (PFE) a Buy, Sell, or Hold?
Pfizer Inc.
NYSE:PFE
$24.25 USD
-$0.23 (-0.94%)
- Volume
- 40.86M
- Average Volume
- 43.12M
- Market Capitalization
- $138.21B
- P/E Ratio
- 18.51
- Dividend Yield
- 7.09%
- Price Target
- $27.00
- Year High
- $28.75
- Year Low
- $23.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.31
- Current Ratio
- $1.25
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Albert Bourla |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | PFE |
| CUSIP | 717081103 |
| CIK | 0000078003 |
| Web | https://www.pfizer.com |
| Phone | 212 733 2323 |
| Currency | USD |
| Employees | 75000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.72 |
| Payout Ratio | 1.31 |
| Current Ratio | 1.25 |
| Quick Ratio | 0.94 |
| Cash Ratio | 0.05 |
Sales & Book Value
| Annual Sales | $62.58B |
| Price / Sales | 2.18 |
| Cash Flow | 1.67 |
| Price / Cash Flow | 14.57 |
| Price / Book | 1.53 |
Price Target and Rating
| Average Stock Price Forecast | $27.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $25.00 |
| Forecast Upside/Downside | -10.19% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 39 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.36 |
| Trailing P/E Ratio | 18.51 |
| PEG Ratio | -3.22 |
| P/E Growth | -3.22 |
| Net Income | $7.77B |
| Net Margin | 11.83% |
| Pretax Margin | 12.49% |
| Return on Equity | 8.37% |
| Return on Assets | 3.61% |
Financials Score
| AltmanZ Score | 2.03 |
| Piotroski Score | 5.00 |
| Working Capital | 8.47B |
| Total Assets | 207.62B |
| Ebit | 10.59B |
| Market Cap | 139.52B |
| Total Liabilities | 117.21B |
Poll Results
About Pfizer Inc. (NYSE:PFE) Stock
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal dis ... ease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
3 of the Best Stocks to Buy for Less Than $100 Right Now
2026-07-14 14:00:00
These stocks offer a good mix of dividends, growth, and long-term stability.
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
2026-07-14 11:51:03
Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results
2026-07-14 11:31:03
PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.
Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?
2026-07-14 10:24:39
The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.
2026-07-14 05:00:00
Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.
Pfizer (PFE) Advances While Market Declines: Some Information for Investors
2026-07-13 18:45:15
In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
2026-07-13 16:47:09
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.
How To Build A $50,000 Dividend Portfolio In Today's Market
2026-07-13 13:45:49
The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield, low payout ratios, and low beta factors, supporting long-term portfolio resilience.
Frequently Asked Questions
-
What is the current Pfizer Inc. (PFE) stock price?
-
Pfizer Inc.(NYSE:PFE) stock price is $24.25 in the last trading session. During the trading session, PFE stock reached the peak price of $28.75 while $23.11 was the lowest point it dropped to. The percentage change in PFE stock occurred in the recent session was --0.94% while the dollar amount for the price change in PFE stock was -$-0.23.
-
PFE's industry and sector of operation?
-
The NYSE listed PFE is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of PFE?
-
Aamir Malik | Executive Vice President & Chief U.S. Commercial Officer
Douglas Lankler | Executive Vice President & Chief Legal Officer
Francesca DeMartino | Chief Investor Relations Officer
Dennis Hancock | Executive VP & Chief Information Officer
David Denton | Executive Vice President & Chief Financial Officer -
How many employees does PFE have?
-
Number of PFE employees currently stands at 75000. PFE operates from 66 Hudson Boulevard East, New York City, NY 10001-2192, US.
-
Link for PFE official website?
-
Official Website of PFE is: https://www.pfizer.com
-
How do I contact PFE?
-
PFE could be contacted at phone #212 733 2323 and can also be accessed through its website. PFE operates from 66 Hudson Boulevard East, New York City, NY 10001-2192, US.
-
How many shares of PFE are traded daily?
-
The average number of PFE shares traded daily for last 3 months was 43.12M.
-
What is the market cap of PFE currently?
-
The market value of PFE currently stands at $138.21B with its latest stock price at $24.25